IMU's cutting-edge platform decodes complex immune challenges to drive breakthroughs and better health outcomes.
This profile is maintained by the Sesamers data desk. Claim it to edit details, post jobs and answer interviews.
€45,600,000
Total raised
-
Valuation
78
Employees
2019
Founded
Latest round
Series A - June 2, 2026
Series A - €45,600,000
June 2, 2026
✓ verified by our desk
Open roles
IMU Biosciences is not hiring through Sesamers right now.
Work here? Claim the profile and post roles.
Claim your profile